Dutch Health Insurers To Reimburse Biosimilars

The Dutch Ministry of Health has said that for the first time, health insurers in the Netherlands will be allowed to include biosimilars in their preference policies. Insurers in the Netherlands can choose to reimburse only a certain selected generic medicine, unless a physician specifies on the prescription that the patient might have an adverse reaction to that particular product. In the same way, insurers can now select a biosimilar for reimbursement. However, only a doctor can decide whether or not to transfer an existing patient on to a biosimilar. BMI notes that the move is an attempt to

To read the full article, please choose one of the following options: